Search

Displaying results 4161 - 4170 of 10000 in total
  1. Drug

    Cetilistat

    go.drugbank.com/drugs/DB06586
    Investigational

    Cetilistat is a novel inhibitor of pancreatic lipase being developed by Alizyme for the treatment of obesity and associated co-morbidities, including type 2 diabetes.

  2. Drug

    Methotrimeprazine

    go.drugbank.com/drugs/DB01403
    Approved

    It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine.

    Synonyms: (-)-(2R)-3-(2-methoxy-10H-phenothiazin-10-yl)-N,N,2-trimethylpropan-1-amine
  3. Drug

    Acadesine

    go.drugbank.com/drugs/DB04944
    Investigational

    It is being developed jointly by PeriCor and Schering-Plough. Acadesine has been granted Orphan Drug Designation for B-CLL in the EU. … Acadesine (AICA-riboside) is a purine nucleoside analog with anti-ischemic properties that is currently being studied (Phase 3) for the prevention of adverse cardiovascular outcomes in patients undergoing

  4. Drug

    Smilagenin

    go.drugbank.com/drugs/DB05450
    Investigational

    in Parkinson’s disease. … P58 is a protein synthesis stimulant acts by restoring levels of proteins that are altered in the ageing brain, reversing the loss of nerve receptors in the ageing brain and potentially allowing for the

  5. Drug

    Torcetrapib

    go.drugbank.com/drugs/DB06281
    Investigational

    Torcetrapib (CP-529414, Pfizer) was developed to treat hypercholesterolemia but its development was halted in 2006 when phase III studies showed excessive mortality in the treatment group receiving a combination

  6. Drug

    Carbendazim

    go.drugbank.com/drugs/DB13009
    Investigational

    Carbendazim has been used in trials studying the treatment of Lymphoma and Unspecified Adult Solid Tumor, Protocol Specific.

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    MB-07803

    go.drugbank.com/drugs/DB05053
    Investigational

    MB07803 is a second generation gluconeogenesis inhibitor for the treatment of type 2 diabetes. It is designed to block the metabolic pathway in the liver that is responsible for producing glucose.

  8. Drug

    Gallium citrate

    go.drugbank.com/drugs/DB17893
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    Dibutylphthalate

    go.drugbank.com/drugs/DB13716
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  10. Drug

    Pozelimab

    go.drugbank.com/drugs/DB15218
    ApprovedInvestigational

    autoimmune hemolysis that are often observed in CHAPLE disease. … CD55-deficient protein-losing enteropathy (PLE), or CHAPLE disease, is an ultra-rare hereditary disease, with fewer than 100 patients diagnosed worldwide or fewer than 10 patients in the US.